(Q44820370)

6 December 2017

title

The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol (English)

1 reference

6 December 2017

1 reference

1 reference

Troy C Sarich

1

1 reference

6 December 2017

Susanne Johansson

2

1 reference

6 December 2017

Kajs-Marie Schützer

3

1 reference

6 December 2017

Ulrika Wall

4

1 reference

6 December 2017

Eva Kessler

5

1 reference

6 December 2017

Renli Teng

6

1 reference

6 December 2017

Ulf G Eriksson

7

1 reference

6 December 2017

publication date

1 April 2004

1 reference

The Journal of Clinical Pharmacology

6 December 2017

published in

1 reference

6 December 2017

volume

44

1 reference

6 December 2017

issue

4

1 reference

6 December 2017

page(s)

388-393

1 reference

Management of oral anticoagulants in the treatment of venous thromboembolism

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Physician practices in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Management of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Interactions of warfarin with drugs and food

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Pharmacokinetic interactions between alcohol and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

Potential for Adverse Drug‐Alcohol Interactions Among Retirement Community Residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004263649

21 January 2018

Identifiers

DOI

10.1177/0091270004263649

1 reference

6 December 2017

1 reference